Annual Report 2016 of GlaxoSmithKline (GSK) Bangladesh Limited

It is a broadly described annual report of GlaxoSmithKline (GSK) Bangladesh Limited in the year of 2016. During the year 2016 GlaxoSmithKline Bangladesh Limited contributed to the government exchequer a sum of BDT 1,683 million. Net Sales of the Company was BDT 6,284 million, against BDT 6,698 million of last year. This represents a 6.19% decline from last year. Cost of Sales Tk. 3,834,031 million. Gross Profit Tk. 2,449,984 million. Net Profit after tax for the year Taka. 644,554 million. Overall profits after tax declined by 22.44%, standing at BDT 645 million. As a result EPS (Earnings per Share) has decreased from BDT 68.99 in 2015 to BDT 53.51 for the reported year.

The Board of Directors has recommended a final dividend of 500% i.e. BDT 50.00 per share of BDT 10.00 each for the year 2016. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of GlaxoSmithKline (GSK) Bangladesh Limited:

  1. Annual Report 2013 of GlaxoSmithKline (GSK) Bangladesh Limited
  2. Annual Report 2014 of GlaxoSmithKline (GSK) Bangladesh Limited
  3. Annual Report 2015 of GlaxoSmithKline (GSK) Bangladesh Limited
  4. Annual Report 2016 of GlaxoSmithKline (GSK) Bangladesh Limited